Group items tagged

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

"If we stand still, we will die. We have to keep moving, and we have to keep changing" said Patrick Gompels, co-owner of Gompels Limited, while emphasising the need for innovation in community pharmacy services, during the recent Pharmacy Business Conference 2024. Centered on the theme 'Pharmacy of Tomorrow,' the conference, held at the Hilton Wembley on April 28, focused on adopting and adapting innovative technology as well as new ways of working and thinking to enhance patient services. Patrick was joined by Mayank Patel of Pearl Chemist Group and Michael Lennox, CEO of Community Pharmacy Somerset (LPC), during the panel discussion on innovation in community pharmacy services, moderated by Reena Barai, pharmacist and owner of S G Barai Pharmacy. On the changes he made at Gompels, Patrick said: "The first thing we did was a complete overhaul of all of our systems. Pretty much everything was stripped down." He shared that Gompels has embraced innovation by partnering with forward-thinking companies like Titan PMR, Drug Comparison, and Real World Analytics to enhance their processes and data analysis capabilities.

The 'Life and Health Sciences Launchpad' has been introduced to focus on the precision medicine sector. It would help businesses and researchers to level up their impact on economic growth within the region. The launchpad has been funded by Innovate UK, part of UK Research and Innovation (UKRI). Kerry Curran, Director of GB & EU Trade in the Department for the Economy hailed the decision to support NI's "trailblazing" sector. She said: "Life and Health Science, including our highly innovative precision medicine cluster, is an area the Department is also prioritising through its 10X Economy Vision, and this Launchpad represents a further endorsement of the world-leading growth potential of precision medicine, and indeed life and health science, in Northern Ireland.

Omnicell Limited, a wholly owned subsidiary of Omnicell - an American healthcare technology company, has signed an agreement with the shareholders of Hub and Spoke Innovations Limited to acquire Hub and Spoke Innovations. Hub and Spoke Innovations Limited is distributor of the Pharmaself24 prescription collection kiosk in Great Britain. The move will complement Omnicell's total solution technology portfolio for retail pharmacy in the UK, including a pack-pick dispensing robot, automated MDS filling machine and eMAR solution, thereby helping pharmacies to improve workflows and offer a 24/7 access to medications and patient care. It will also help community pharmacies achieve their goals, as they increasingly look at ways to make their businesses more efficient and free up staff to offer more pharmaceutical care and services to patients. In short, the deal would enable Omnicell to offer a wider range of digital technologies to streamline retail pharmacy operations, allowing pharmacists to spend more time with patients and focus on value-added, revenue-generating healthcare services, such as vaccinations.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the collaboration between industry and the NHS to improve patient outcomes across the UK. Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these areas continues to be below the average of similar countries in Europe. The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations and industry have helped to tackle unwarranted variation in the uptake of innovative medicines. Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment. The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

The new 'How to Involve and Engage Patients on Digital Health Tech Innovation' learning module has been created specifically to support the development and delivery of patient-centric technologies, at a time of critical digital transformation in the NHS. The foundation level module will be freely available at www.orcha-digitalhealthacademy.com and on the Health Education England NHS Learning Hub (learninghub.nhs.uk). No training previously exists on conducting effective patient and public involvement and engagement (PPIE), leading to wasted resource on unsuitable technologies at a time when the healthcare system simply cannot afford it. The module aims to educate innovators who are creating new technology, and the clinicians who are prescribing these solutions. Crucially, the module also provides valuable support to the 500 NHS clinicians who are on the Clinical Entrepreneur Programme. The module is an introduction to the first evidence-based framework for PPIE, launched by the University of Plymouth, the AHSN Network (the national voice of the 15 academic health science networks in England) and Boehringer Ingelheim UK & Ireland. It helps to fast-track learning for the EnACT principles described in the framework, outlining how to involve patients in product innovation and critical issues such as data privacy, intellectual property, inclusivity, reimbursement, useability, and recruitment of patients.

Haleon is enhancing its research and development (R&D) capabilities and accelerating its new product innovation pipeline with a $54 million (£43.49 million) investment in its global R&D centre of excellence in Richmond, Virginia, USA. This investment is in addition to the company's annual R&D budget of approximately £300 million. The Richmond site, one of Haleon's three global R&D centres of excellence, alongside facilities in Weybridge, UK, and Suzhou, China, provides the global scale necessary for the company to deliver disruptive and locally relevant brand innovations across over 170 markets worldwide. The upgraded facility will feature new, state-of-the-art laboratories designed to enable development of innovations across ingredients, formulations, flavours, formats and packaging for Haleon's Over-the-Counter (OTC) and Vitamins, Minerals and Supplements (VMS) categories. Franck Riot, Haleon's chief R&D officer, emphasised the critical role of R&D in the company's success, stating, "R&D is the cornerstone of our business and the innovation engine behind our category-leading brands." "Consumers trust our products because they trust our science - so investing in R&D is vital for driving consumer preference for our brands."

The life cycle management company, Pharmanovia, has appointed Nivedita Valentine as associate vice president of Product Innovation. Ms Valentine will oversee the company's product innovation operations and decision-making as Pharmanovia continues to focus efforts on both, identifying new prospects to enhance lifecycle management of its brands through incremental innovation. She will report to interim chief scientific officer Stephen Deacon and help bridge unmet patient needs with the help of novel therapies, originating both from in-house development and through partnerships. Ms Valentine currently holds positions on the value-added medicines committee within Medicines for Europe and the International Rare Diseases Research Consortium (IRDiRC) Task Force on Drug Repurposing Guidebook. Pharmanovia CEO Dr James Burt commented: "Digitalisation and utilising the latest technological innovation are notable areas of acceleration within the pharma industry and Nivedita's appointment will ensure iconic brands will continue to be improved, supported, and used sustainably.

Moderna has joined one of the UK's leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK. The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK's life sciences ecosystem. The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions. The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world's largest, most innovative, and most successful pharmaceutical firms. Darius Hughes, UK General Manager, Moderna, said: "We are delighted to join the ABPI - this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND. This extends the UK government's support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years. FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development. Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: "Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives."

Homecare.co.uk's famed Top 20 UK awards have turned out a multiple winner, with Blue Angel Care a highlight. Blue Angel Care took two prestigious gongs , Top 20 Homecare Group Provider in the UK and Top 20 Home Care Providers in South East England. Finding innovative ways to circumnavigate the difficulties of the coronavirus pandemic, the homecare specialists have grown to a nationwide team of more than 200 care givers. Dariusz Motka, Managing Director and Co-Founder of Blue Angel Care, said in a statement: "We are eternally grateful to the readers and reviewers of Homecare.co.uk for honouring us with, not one, but two awards." Praising his staff, Dariusz added : "More so, we are all grateful to the incredibly hardworking and professional staff that help to train so many capable carers every single week."

Researchers at the University of Oxford have received a grant of up to £600,000 from Cancer Research UK to develop the world's first vaccine to prevent ovarian cancer. Named OvarianVax, the innovative vaccine aims to train the immune system to recognise and attack the earliest stages of ovarian cancer. Ovarian cancer is the sixth most common cancer among women in the UK, with approximately 7,500 new cases diagnosed annually-equating to about 21 cases each day. It is also a leading cause of cancer-related deaths in women, with around 4,100 deaths each year, accounting for five per cent of all cancer deaths in UK females. Projections suggest that by 2038-2040, there could be around 9,400 new cases of ovarian cancer annually in the UK. Several factors influence a person's risk of developing ovarian cancer, including age, genetics, hormone replacement therapy (HRT), smoking, asbestos exposure, medical conditions such as endometriosis or diabetes, and obesity. Faults in the inherited genes, particularly BRCA1 and BRCA2, are linked to a higher risk of ovarian cancer, contributing to 5-15 per cent of cases.

The Galien Foundation recently announced the winners of the 2024 Prix Galien UK Awards, with the University of Oxford receiving accolades for its groundbreaking contributions to public sector innovation through the PRINCIPLE and PANORAMIC Trials. These trials, spearheaded by Oxford's team of experts, have set a new standard for scientific innovation aimed at improving global health outcomes. Led by University of Oxford, the PRINCIPLE and PANORAMIC Trials epitomize a remarkable collaboration aimed at combating the COVID-19 pandemic.

Alex Potter is the new Managing Director of PharmAssist Solutions UK, an online purchasing solution utilised by over 1,100 community pharmacies. Potter, previously the Director of Digital at Phoenix UK, will succeed the current MD, Amar Randhawa, and has expertise in the digital landscape across the industry, PharmAssist Solutions said in a statement. "We are delighted to have Alex on board," said Stuart Lucas, Chair of the PharmAssist Board. "His profound grasp of the pharmacy sector, combined with his expertise in digital innovation, will spearhead PharmAssist's evolution to meet the dynamic demands of its clientele." Meanwhile, Lucas expressed his gratitude and appreciation to Amar for his hard work and dedication over the last decade. "Amar, as the founder of PharmAssist, played a pivotal role in achieving numerous significant milestones and driving its growth," he added. "We wish him every success in his future endeavors."

Ceuta Group has appointed Michael Yates as chief operating officer (COO). In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services and unlock new opportunities for its clients. Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior commercial and managing director roles across Europe, Africa and Asia. During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene. With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.

The government has joined hands with Prostate Cancer UK to launch a massive screening trial in the country next year. Called TRANSFORM, the trial will use innovative screening methods like an MRI scan to detect prostate cancer, which is the most common cancer in men in the UK. The trail is scheduled for launch in Spring 2024, and recruitment is likely to begin in Autumn 2024. For the £42 million trial, the government will invest £16 million through the National Institute of Health Research, and £26m will be provided by Prostate Cancer UK. The Department of Health and Social Care (DHSC) believes that thousands of men's lives could be saved each year if prostate cancer is detected early with effective screening methods.

The UK government has announced the launch of a new joint public-private investment programme aimed at accelerating patient access to cutting-edge treatments, enhancing clinical trials, and bolstering the country's medicines manufacturing capabilities. Supported by up to £400 million of investment, the Voluntary Scheme for Branded Medicine Pricing, Access and Growth (VPAG) Investment Programme is set to inject significant resources into the UK's health and life sciences sector over the next five years. Believed to be the world's first major public-private collaboration of this scale globally, the VPAG Investment Programme is designed to boost economic growth and the global competitiveness of the UK's life sciences sector. It aims to strengthen the NHS by supporting innovative research and creating 18 new clinical trial hubs to fast-track the development of new medicines for patients. The programme will also streamline processes to ensure the rapid transition of new treatments from labs to wards, providing patients with faster access to cutting-edge treatments. Health and Social Care Secretary Wes Streeting hailed this private investment as "a significant vote of confidence in the UK" highlighting that it will fast-track the next generation of treatments to NHS patients.

Charac, an NHS-integrated one-stop platform for independent community pharmacies, and Positive Solutions, the fastest growing pharmacy IT provider in the UK, have agreed on a collaboration to support community pharmacies through new integrated technology platform - MyHealthHub. The tech platform aims to give pharmacies a powerful and compelling tool to both help retain and attract new patients. The app will also allow the over 7,200 independent high street pharmacies which are lacking a digital footprint to compete with larger online pharmacies by providing them with an online presence. The long-term strategic partnership brings together Charac's innovative approach to patient relationship management and Positive Solutions trusted expertise in digital solutions for pharmacy. With Positive Solutions' Analyst PMR used daily by 16,000 pharmacy team members to process over 87 million scripts and 180 million items, the collaboration will help transform patient engagement and continue driving service business to pharmacies across the UK using a new innovative, integrative technology platform, MyHealthHub. MyHealthHub will not only integrate with Analyst PMR, but also forms part of an entire new technology ecosystem from Positive Solutions, the Hx platform and will be entirely interoperable.